The topical issues of clinical pharmacology of clarithromycin

O. O. Yakovleva, A. B. Ilchenko

Abstract


Recently, as evidenced by numerous publications and surveys on the topic, the interest in clarithromycin is not reduced. This drug has a wide range of the antibacterial activity, is able to penetrate into cells and create stable and high tissue concentration exceeding the level of the drug in the blood serum. However, in recent years, more attention is paid to the study of nonantibacterial effects of clarithromycin. In modern macrolides, in particular in clarithromycin, the anti-inflammatory, immunomodulatory and mucoregulatory properties have been found. The primary mechanism of the immunomodulatory action of macrolides today is considered to be their ability to affect NF-kB-and MAPK-dependent signaling pathways of cells. Under the effect of clarithromycin the decrease in the synthesis and/or secretion of pro-inflammatory (IL-1, -6, -8, tumour necrosis factor (TNF)) and the increase in the secretion of anti-inflammatory cytokines (IL-2, -4, -10) are observed. The effectiveness of the indirect antimicrobial action of clarithromycin is intensively studied in vitro and in vivo, and it further expands our understanding of the therapeutic possibilities of this drug.


Keywords


clarithromycin; indirect antibacterial effects; nonantibacterial effects immunomodulatory effect

Full Text:

PDF

References


Волосовец А.П., Кривопустов С.П. Макролиды в практике современной педиатрии. — К.: Четверта хвиля. - 2009. — 192 c.

Зузова А.П., Белькова Ю.А. // Фарматека. – 2007. - №17. – С22-28

Фещенко Ю.И., Яшина Л.А. // Здоров’я України. – 2008. -№16. – С. 42-43.

Aikaterini Spyridaki A., Antonopoulou A., Raftogiannis M. et al. // Antimicrobial Agents and Chemotherapy. – 2012. – Vol. 56. – P. 3819–3825.

Amado-Rodríguez L., González-López A., López-Alonso I. et al. // Respiratory Research. - 2013. - Vol .14. – P. 52-57.

Benerjee D., Honeybourne D., Khair O.A. // Treat Respir Med. - 2004. – Vol. 3. – P. 59–65.

Buyck J.M., Plésiat P., Traore H. Et al. // Clinical Infectious Diseases. - 2012. –Vol. 55(4). – P. 534–542.

Giamarellos-Bourboulis E. J., Peche J.-C., Routsi C. et al. // Clinical Infectious Diseases. - 2008. – Vol. 46. – P. 1157–1164.

Foroutana S.M., Shafaatib A., Zarghib A. et al. // Iranian Journal of Pharmaceutical Research. - 2013. – Vol. 12. – P. 65-69.

Hirata K., Nishizawa H., Suzuki T. et al. // J.Gastroenterol Hepatol. – 2010. - Vol. 25. - P. 75-79.

Kohyama T., Takizawa H., Yamauchi Y. et al. // Respir Med. - 2008. - Vol. 102(12). – P. 1769-1776.

Kozlov R.S., Sivaja O.V., Stratchounski L.S. 7-years monitoring of resistance of clinical S. Pneumoniae in Russia: results of prospective multicenter study (PEHASus) / // Proc 45th , Washington DC ICAAC. - 2005.

Larissa L., Pereira D.C., Paiva R.M. et al. // BMC Microbiology. - 2012. – Vol. 12. – P. 196-199.

Morita Y., Tomidaand J., KawamuraY. Responses of Pseudomonas aeruginosa to antimicrobials // Antimicrobials, Resistance and Chemotherapy. - 2014. – Vol. 4. – P. 422-428.

Nixon L.S., Boorman J., Papagiannis A.J. et al. // Respiratory Medicine. - 2007. – Vol. 101. – P. 2409-2415.

Restrepo M.I., Mortensen E.M., Waterer G.W. et al. // Eur Respir J. - 2009. - Vol. 33. – P. 153–159.

Shinahara W., Sawabuchi T., Takahashi E. et al. // PLoS ONE. – 2013. - Vol. 8(7). – P. 124-130.

Tagaya E., Kondo M., Tamaoki J. et al. // Chest. - 2002. – Vol. 122. – P. 213–218.

Tamaoki J. // Chest. - 2004. – Vol. 125. – P. 41–51.

Tanabe T., Kanoh S., Tsushima K. et al. // Am. J. Respir. Cell Mol. Biol. – 2011. - Vol. 45, № 5. - P. 1075–1083.

Walkey Allan J., Wiener R. S. // Chest. - 2012. – Vol. 5. – P. 141-143.

Wozniak D.J., Keyser R. // Chest. - 2004. – Vol. 125. – P. 62–69.


GOST Style Citations






DOI: https://doi.org/10.24959/88913

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)